第三次全国幽门螺杆菌感染若干问题共识报告

被引：47

作者：

胡伏莲

机构：

[1] 中华医学会消化病学分会幽门螺杆菌学组

[2] 北京大学第一医院消化内科

来源：

中华内科杂志 | 2008年 / 04期

关键词：

D O I：

暂无

中图分类号：

R686 [筋腱、韧带、滑囊疾病及损伤];

学科分类号：

1002 ; 100210 ;

摘要：

迄今为止,我国已发布了两次关于幽门螺杆菌(H.pylori)若干问题的共识意见,第一次是1999年4月海南三亚会议提出的《幽门螺杆菌若干问题共识意见》(海南共识);第二次是2003年10月提出的《幽门螺杆菌共识意见(2003·安徽桐城)》(桐城共识)。4年多来,我国学者对 H.pylori 处理中的一些重要问题又有了新的认识和见解,结合欧洲 Maastricht Ⅱ及Ⅲ共识报告,中华医学会消化病学分会幽门螺杆菌学组于2007年8月10-12日于江西庐山召开了第三次全国幽门螺杆菌共识会议,来自全国的60多名专家对 H.pylori 感染若干问题达成了新的共识,提出了《第三次全国幽门螺杆菌感染若干问题共识报告》(庐山共识)。

引用

共 20 条

[1] Meta-analysis:: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori [J].

Fischbach, L. ;

Evans, E. L. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (03) :343-357

[2] Levofloxacin-vs. ranitidine bismuth citrate-containing therapy after H-pylori treatment failure [J].

Gisbert, Javier P. ;

Gisbert, Jose Luis ;

Marcos, Santiago ;

Moreno-Otero, Ricardo ;

Pajares, Jose Maria .

HELICOBACTER, 2007, 12 (01) :68-73

[3] Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures [J].

Gisbert, J. P. ;

Gisbert, J. L. ;

Marcos, S. ;

Moreno-Otero, R. ;

Pajares, J. M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (10) :1469-1474

[4] Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection [J].

Cheon, JH ;

Kim, N ;

Lee, DH ;

Kim, JM ;

Kim, JS ;

Jung, HC ;

Song, IS .

HELICOBACTER, 2006, 11 (01) :46-51

[5] Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children:: a randomized trial [J].

Francavilla, R ;

Lionetti, E ;

Castellaneta, SP ;

Magistà, AM ;

Boscarelli, G ;

Piscitelli, D ;

Amoruso, A ;

Di Leo, A ;

Miniello, VL ;

Francavilla, A ;

Cavallo, L ;

Ierardi, E .

GASTROENTEROLOGY, 2005, 129 (05) :1414-1419

[6] American gastroenterological association technical review on the evaluation of dyspepsia [J].

Allison, JA ;

Inadomi, JM ;

Ladabaum, U ;

McQuaid, K ;

Metz, D .

GASTROENTEROLOGY, 2005, 129 (05) :1756-1780

[7] Update on therapeutic options for Helicobacter pylori-related diseases [J].

Mégraud F. .

Current Infectious Disease Reports, 2005, 7 (2) :115-120

[8] Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection [J].

Nista, EC ;

Candelli, M ;

Zocco, MA ;

Cazzato, IA ;

Cremonini, F ;

Ojetti, V ;

Santoro, M ;

Finizio, R ;

Pignataro, G ;

Cammarota, G ;

Gasbarrini, G ;

Gasbarrini, A .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (10) :1241-1247

[9]

A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding.[J].D Schilling;A Demel;H.E Adamek;T Nüsse;E Weidmann;J.F Riemann.Digestive and Liver Disease.2003, 4

[10] An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia:: Resolving the discrepancy between systematic reviews [J].

Moayyedi, P ;

Deeks, J ;

Talley, NJ ;

Delaney, B ;

Forman, D .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12) :2621-2626

← 1 2 →